Medicine and HealthNature
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
P. Mlcochova, S. A. Kemp, et al.
The B.1.617.2 (Delta) variant of SARS-CoV-2 poses a significant challenge as it exhibits reduced sensitivity to neutralizing antibodies and increased replication efficiency. Conducted by a diverse team of authors, including Petra Mlcochova and Steven A. Kemp, this research highlights the urgent need for continued infection control measures to combat the Delta variant's immune evasion strategies.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
M. Gagne, B. J. Flynn, et al.
Biology
SARS-CoV-2 variant biology: immune escape, transmission and fitness
A. M. Carabelli, T. P. Peacock, et al.
Biology
Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia
J. Y. L. Fu, M. H. Pukhari, et al.
Biology
CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection
Z. Liu, X. Gao, et al.
